- Home
- MIRM vs BWIN Comparison
MIRM vs BWIN Comparison
Compare MIRM & BWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- BWIN
- Stock Information
- Founded
- MIRM 2018
- BWIN 2011
- Country
- MIRM United States
- BWIN United States
- Employees
- MIRM N/A
- BWIN N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- BWIN Specialty Insurers
- Sector
- MIRM Health Care
- BWIN Finance
- Exchange
- MIRM Nasdaq
- BWIN Nasdaq
- Market Cap
- MIRM 3.3B
- BWIN 2.9B
- IPO Year
- MIRM 2019
- BWIN 2019
- Fundamental
- Price
- MIRM $67.93
- BWIN $32.84
- Analyst Decision
- MIRM Strong Buy
- BWIN Buy
- Analyst Count
- MIRM 9
- BWIN 8
- Target Price
- MIRM $73.89
- BWIN $44.00
- AVG Volume (30 Days)
- MIRM 661.2K
- BWIN 1.1M
- Earning Date
- MIRM 08-06-2025
- BWIN 08-05-2025
- Dividend Yield
- MIRM N/A
- BWIN N/A
- EPS Growth
- MIRM N/A
- BWIN N/A
- EPS
- MIRM N/A
- BWIN N/A
- Revenue
- MIRM $429,161,000.00
- BWIN $1,461,046,000.00
- Revenue This Year
- MIRM $36.76
- BWIN $13.10
- Revenue Next Year
- MIRM $17.48
- BWIN $14.39
- P/E Ratio
- MIRM N/A
- BWIN N/A
- Revenue Growth
- MIRM 62.33
- BWIN 11.44
- 52 Week Low
- MIRM $36.86
- BWIN $28.66
- 52 Week High
- MIRM $69.00
- BWIN $55.82
- Technical
- Relative Strength Index (RSI)
- MIRM 82.95
- BWIN 38.12
- Support Level
- MIRM $50.25
- BWIN $28.66
- Resistance Level
- MIRM $67.45
- BWIN $34.31
- Average True Range (ATR)
- MIRM 2.89
- BWIN 1.71
- MACD
- MIRM 1.38
- BWIN -0.18
- Stochastic Oscillator
- MIRM 94.29
- BWIN 36.17
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About BWIN The Baldwin Insurance Group Inc. Class A Common Stock
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.